The results in this study were similar to those published to date, which show higher Cdk1 expression and activity in Hodgkin's lymphomas, colorectal cancer, prostate cancer, gastric lymphoma, and childhood acute lymphoblastic leukemia [5–9]. This evidence concerns the gene CDK1 and prostate carcinoma.